Table 2. Univariate analysis: 5-year progression-free survival (PFS).

VARIABLE	5 year PFS HR (95% CI)	P value
Gender (Female/male)	0.47 (0.2–1.05)	0.07
Age	0.98 (0.94–1.01)	0.25
ECOG PS	2.8 (1.9–4.3)	<0.0001
Tumor size ≥4 cm	4.0 (1.4–11.4)	0.009
Nodal status (positive vs negative)	4.24 (1.6–11.3)	0.004
Pretreatment Hb<120 g/L	5.6 (2.2–14.1)	<0.0001
RT (n = 17) vs CRT (n = 72)	2.0 (0.7–5.6)	0.19
Response at three months	0.44 (0.29–0.73)	0.002
P16 DAB score	0.67 (0.34–1.31)	0.24
P16 DAB score 3	0.37 (0.75–1.86)	0.27
HPV16 CISH	1.22 (0.69–2.18)	0.49
P16 AQUA tumor score, quartiles	1st – 0.62 (0.15–2.61)	0.65
	2nd – 0.95 (0.22–4.02)	0.94
	3rd – 0.21 (0.02–1.77)	0.15
	4th – 1.0
P16 AQUA tumor score>244	3.5 (1.04–11.8)	0.04
P16 AQUA tumor score>244 and higher pretreatment Hb (≥120 g/L)	8.4 (1.8–38.6)	0.006

ECOG PS: Eastern Cooperative Oncology Group Performance Status; RT: radiotherapy; CRT: chemoradiotherapy; Hb: hemoglobin; DAB: diaminobenzydene, CISH: chromogenic in situ hybridization